“We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data,” said Mark Jensen, chair and member of the special committee of 23andMe's board.
Biotechnology company Regeneron purchasing 23andMe for $256 million
→
Mark Jensen, chair of the company's Special Committee of the Board of Directors, said in a statement at the time that the firm was "committed to continuing to safeguard customer data and being transparent about the management of user data going forward, and data privacy will be an important consideration in any potential transaction."
House panel launches probe into 23andMe bankruptcy, steps taken to protect genetic data
→
